Application Detail

Description of Medical Service

The ArteraAI Prostate Biopsy Assay is a software device based on artificial intelligence that assesses clinical information about a patient with localised prostate cancer in combination with digital images from the patients’ prostate biopsy.
The AI then predicts whether a patient with intermediate risk localised prostate cancer who is planned to undergo curative-intent radiotherapy would benefit from hormone therapy in the short-term and their longer term prognosis.

Description of Medical Condition

Prostate cancer is cancer that forms in the tissues of the prostate. Australia has one of the highest incidence rates of prostate cancer with around 1 in 6 men diagnosed by age 85. Advances in early detection and management focus on minimising harm and reducing overdiagnosis and overtreatment.

Reason for Application

New MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 240 KB)
Application Summary (Word 26 KB)

PICO Set (PDF 1380 KB)
PICO Set (Word 1325 KB)

Consultation Survey

Consultation Survey

PASC Consultation
PASC consultation closes Friday 8 November 2024. Any consultation received after this date will automatically be included in the MSAC consultation for this application.

MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC email bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.

For further information please refer to PASC, ESC, MSAC Key Dates

For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

12-13 December 2024

ESC

-

MSAC

-